Oncotarget

Research Papers:

Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials

Mengmeng Wang, Huimin Tian, Gang Li, Tingwen Ge, Yudi Liu, Jiuwei Cui and Fujun Han _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:48375-48390. https://doi.org/10.18632/oncotarget.10237

Metrics: PDF 2153 views  |   HTML 2203 views  |   ?  


Abstract

Mengmeng Wang1, Huimin Tian1, Gang Li2, Tingwen Ge1, Yudi Liu1, Jiuwei Cui1, Fujun Han1

1Cancer Center, The First Hospital of Jilin University, Changchun, China

2Department of Thyroid and Breast Surgery, No.458 Hospital of People’s Liberation Army, Guangzhou, China

Correspondence to:

Fujun Han, email: [email protected]

Keywords: adjuvant chemotherapy, concurrent chemoradiotherapy, meta-analysis, nasopharyngeal carcinoma, neoadjuvant chemotherapy

Received: January 21, 2016    Accepted: May 30, 2016    Published: June 23, 2016

ABSTRACT

Purpose: We did a meta-analysis to compare the efficacy and safety of neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiotherapy (CCRT) versus CCRT with or without adjuvant chemotherapy (AC) for patients with locoregionally advanced nasopharyngeal carcinoma based on randomized controlled trials.

Methods: We searched PubMed, Embase, Web of Science, ClinicalTrials.gov, Chinese National Knowledge Infrastructure, and meeting proceedings of major relevant conferences to identify published and unpublished randomized controlled trials. Progression-free survival (PFS) was the primary endpoint.

Results: This meta-analysis included 9 randomized clinical trials with 2215 patients. NACT followed by CCRT significantly improved PFS (HR=0.68, 95% CI 0.56 – 0.81, P < 0.001) compared versus CCRT with or without AC, and no heterogeneity was observed (I2 = 0.0%, P = 0.975). NACT was associated with a significant improvement in overall survival (HR = 0.64, 95% CI 0.49 – 0.84, P = 0.001; I2 = 0.0%, P = 0.467) and distant failure-free survival (HR = 0.72, 95% CI 0.53 – 0.97, P = 0.031; I2 = 0.0%, P = 0.744). No significant benefit was shown by NACT for locoregional control. NACT with CCRT increased risks of grade 3 – 4 anemia, thrombocytopenia, leukopenia, and fatigue, compared versus CCRT with or without AC.

Conclusions: Our meta-analysis confirmed that the addition of NACT to CCRT significantly improved PFS and OS versus CCRT with or without AC for locoregionally advanced nasopharyngeal carcinoma. These results may alter the standard of care - CCRT with or without AC, for locoregionally advanced nasopharyngeal carcinoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10237